Indian Journal of Hematology and Blood Transfusion最新文献

{"title":"Insight Into Aetiology and Severity of Hemolysis Associated with Immunoproteins on Red Cell Surface in Direct Antiglobulin Test Positive Auto-immune Hemolytic Anemia","authors":"Suhasini Sil, Daljit Kaur, Gita Negi, Ashish Jain, Uttam Kumar Nath","doi":"10.1007/s12288-024-01805-y","DOIUrl":"https://doi.org/10.1007/s12288-024-01805-y","url":null,"abstract":"<p>The study aimed to find out the correlation of positive direct antiglobulin test (DAT) with features of autoimmune hemolysis in patients presenting to a tertiary care center in Northern India. Patient history, lab findings, and immune-hematological findings which can influence the management of patients with auto-immune hemolytic anemia were studied. DAT helps to differentiate immune hemolysis from non-immune hemolysis in patients with hemolytic anemia. A prospective study over 18 months was performed on DAT-positive samples of patients showing features of auto-immune hemolysis. The laboratory markers of hemolysis were correlated with immune-hematological studies like elution-adsorption, antibody specificity, and titer. Out of 1371 requests received for Immuno-hematological workup of patients with hemolysis, 92 (6.71%) met the inclusion criteria. Thirty (32.6%) patients were diagnosed with primary (Idiopathic) Auto-immune Hemolytic Anemia (AIHA), and the remaining 62(67.3%) patients had secondary AIHA. The gender distribution in primary AIHA was male: female as 1:2.7, while in secondary AIHA it was observed as male: female to be 1:1.3.The median age for primary AIHA was found to be 23.7 years (range 1 year to 48 years), and for secondary AIHA it was found to be 44.6 years (range 2 to 85 years). Of all AIHA patients tested, 85.8% showed the presence of warm autoantibodies in their sera while 7.6% had mixed-type AIHA and the remaining 6.5% had cold autoantibodies. The study highlights a strong association between higher strength of DAT positivity, multiple antibodies/immunoglobulins with complements coating red cells, and a higher titer of IgG and IgG1 &amp; IgG3 subclass with the severity of hemolysis.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Immunosuppressive Therapy in Aplastic Anemia—A Single Centre, Prospective Study of 158 Patients from a Tertiary Care Centre in India","authors":"Mahathi Krishnan, Deepak Amalnath","doi":"10.1007/s12288-024-01794-y","DOIUrl":"https://doi.org/10.1007/s12288-024-01794-y","url":null,"abstract":"<p>Immunosuppressive therapy (IST) with Antithymocyte globulin (ATG) and cyclosporine is the therapy of choice in aplastic anemia (AA) patients who are more than 40 years of age and younger patients who do not have matched sibling donor for stem cell transplant (SCT). The overall response rate to IST is approximately 65%. The two preparations of ATG that are available in India are Atgam (Pfizer) and Thymogam (Bharat serum, India). Most of the published studies, from India, have used ATGAM. We present the largest study on IST (with Thymogam) from India. This is a single centre prospective study conducted in a tertiary care institute in southern India, from July 2016 to June 2022. All patients of age more than 13 years with diagnosis of aplastic anemia were included. Those with inherited bone marrow failure syndromes were excluded. Severity of AA and response rate was classified based on standard criteria. Patients were followed up till discharge and then monthly for at least 6 months. A total of 158 patients ( males-85, females- 73) received IST (Thymogam plus cyclosporine).Most of the patients had non severe AA(58%) followed by severe (28%) and very severe AA(14%). At 6 months post IST, the overall response rate (ORR) was 66% (complete response- 2% and partial response -64%) while the mortality rate was 13%.The ORR was 64% at 12 months and 61% at 24 months after IST. Age, Gender and severity at presentation did not influence response rates.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Low-cost Paper Based Haemoglobin Solubility Test for the Rapid Diagnosis of Sickle Cell Disease","authors":"Minakshi Swain, Prasanta Purohit, Samira Kumar Behera","doi":"10.1007/s12288-024-01799-7","DOIUrl":"https://doi.org/10.1007/s12288-024-01799-7","url":null,"abstract":"<p>In this study, we describe and compare a simple, rapid, low cost, point-of-care diagnostic paper-based test for screening of sickle cell disease, which is based on principle of haemoglobin solubility. This observational study was carried out in 384 cases advised for screening of haemoglobin disorders by HPLC. All the cases were subjected to both HPLC and modified sickle cell paper solubility test simultaneously. The results of both the test were compared accordingly. Further to check the minimum level of HbS that can be identified by paper solubility test, a sample dilution method was used and analyzed. Out of 384 cases, 131 cases were found to have an HbS window in the HPLC report and rest 263 cases were found to have either normal or other haemoglobin variants. The paper solubility test also showed the similar results with 100% of sensitivity and specificity. Further, a &gt; 5% of HbS can be traced and identified by paper solubility test. The paper-based haemoglobin solubility test was seen to be capable of distinguishing sickle cell patients from non sickle cell blood samples with a high degree of accuracy. It is a very rapid test that can be performed by a person with minimal training at community level (field study). The paper based Hb Solubility test is a low cost, easy, rapid, accurate, point of care and reproducible screening test for sickle cell patients.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141254407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic B-cell Lymphoma / Leukemia with Prominent Nucleoli","authors":"Leena Gupta, Anita Chopra","doi":"10.1007/s12288-024-01795-x","DOIUrl":"https://doi.org/10.1007/s12288-024-01795-x","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141194922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia","authors":"Xiaoyu Liu, Lin Yang, Kunping Guan, Zhen Chen, Hua Yang","doi":"10.1007/s12288-024-01773-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01773-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aims to investigate the increased toxicity of Cytarabine (Ara-c) by knockdown of chromosome segregation 1-like (CSE1L) in acute myeloid leukemia(AML) cells(Kasumi-1, U937, and THP-1 cells) and to explore its possible mechanisms.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Target gene silencing was achieved using the shRNA-mediated lentivirus method. Apoptosis was identified using the Annexin V PE/7-AAD double-staining assay. Cell viability was assessed with the Cell Counting Kit-8 (CCK-8) assay. Protein expression was detected by Western blotting.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In vitro, knocking down CSE1L promoted caspase-3 and caspase-9 proteins expression and induced apoptosis in AML cells. Knockdown of CSE1L enhanced AML cells' sensitivity to Ara-c. knockdown of CSE1L reduced the expression levels of p-JKA2 and p-STAT3 proteins, while no significant difference was observed in the expression levels of total JAK2 and STAT3 proteins. Furthermore, JAK2 overexpression reversed the increase in Ara-c toxicity to AML cells caused by CSE1L knockdown.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>In conclusion, our study reveals that CSE1L is a potential therapeutic target for overcoming Ara-c resistance in AML cells. Thus, we have gained new insights into the oncogenic process of CSE1L in AML cells and raised the prospect of knockdown of CSE1L in AML in combination with cytarabine-targeted therapy.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141172562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occurrence of Monoclonal Band in Alpha Region on Serum Electrophoresis in Multiple Myeloma: A Diagnostic Conundrum","authors":"Nisha Duggal, Mahendra Kumar, Pankaj Malhotra, Arihant Jain, Ritu Aggarwal","doi":"10.1007/s12288-024-01793-z","DOIUrl":"https://doi.org/10.1007/s12288-024-01793-z","url":null,"abstract":"<p>The presence of an M-band in serum and/or urine electrophoresis is a crucial diagnostic indicator for multiple myeloma and other plasma cell dyscrasias. Conventionally, on serum protein electrophoresis (SPEP), the M-band is observed as a sharp spike (M-spike), typically in the gamma region, occasionally in the beta region, and rarely in the alpha region. However, the infrequency of M-bands in the alpha region raises the possibility of overlooking them when coexisting with normal bands. This study underscores the significance of considering the potential discovery of M-bands in unusual sites, particularly in the alpha-2 region. This retrospective study spanned three years and involved conducting serum and urine protein electrophoresis followed by serum and urine immunofixation electrophoresis on a semi-automated platform (Helena Biosciences, Europe) using agarose gel and serum protein 6-band format kits. We identified five cases of multiple myeloma presenting with a monoclonal band in the alpha-2 region on SPEP and UPEP. Subsequent immunofixation electrophoresis confirmed these bands to be monoclonal bands in the lambda lane. In suspected cases of multiple myeloma, even in the absence of an M-band in the gamma region, heightened prominence in the alpha or beta region warrants further investigation through immunofixation electrophoresis (IFE).</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141153818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study","authors":"Octavio Martínez Villegas, Norma Eryca Alatoma Medina, Marcos Javier Romero Vázquez, Juan Carlos Andrade Colmenero, Bertha Elizabeth Tirado López, Ana Isabel Toala Fernández, Betzayda Valdez Garibay, Blanca Olivia Murillo Ortíz, Lauro Fabián Amador Medina","doi":"10.1007/s12288-024-01787-x","DOIUrl":"https://doi.org/10.1007/s12288-024-01787-x","url":null,"abstract":"<p>Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, and the Hispanic race has the highest incidence worldwide<b>.</b> Disparities in survival rates exist among different regions of the world. Due to this heterogeneity and possible differences in the outcomes within Mexico, the aim of this study was to analyze the clinical outcomes of cohort of pediatric patients with ALL treated in a highly specialized medical unit located in the Bajio region of Mexico. Observational retrospective study of a cohort of pediatric patients with ALL treated in a tertiary-level hospital in the Bajio region of Mexico, between January 2016 and December 2021. A total of 146 patients were included with a median age of 7 years. The 68.5% of patients were at high risk. CNS involvement was present in 2.7%, and Philadelphia chromosome positive in 2%. Cytogenetic analysis was performed in 16.4% patients. The median follow-up of entire cohort was 32 months. The most frequently administered chemotherapy treatment was Total Therapy XV in 79.5% of patients. The complete remission rate was 89%. Refractory disease was present in 2.7%. Induction-related mortality was 8.2%. The relapse rate was present in 26%. The 3-years overall survival was 57.5%, and the 3-years event-free survival was 53.4%. A more aggressive course and worse survival occur in our cohort of pediatric patients with ALL<b>.</b> Strategies should be proposed inside Mexico and other low-middle income countries with the aim of improving the overall survival.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141060527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinatumomab Bridge Therapy for Mitigating Chemotoxicity in Children with Acute Lymphoblastic Leukemia","authors":"Ayça Koca Yozgat, Özlem Arman Bilir, İkbal Ok Bozkaya, Hüsniye Neşe Yaralı","doi":"10.1007/s12288-024-01791-1","DOIUrl":"https://doi.org/10.1007/s12288-024-01791-1","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic Co-Inheritance of Hb Leiden (HBB:c.22_24delGAG), Hb Q-Thailand (HBA1:c.223G > C) and Deletional Alpha Thalassemia in a Young Chinese Male","authors":"Tianfeng Ren, Liang Liang, Youqiong Li","doi":"10.1007/s12288-024-01789-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01789-9","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140968608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre","authors":"Rup Jyoti Sarma, Lakhan Kashyap, Anne Srikanth, Tanmoy Mondal, Yashwant Kashyap, Ravindra Nandhana, Suresh Kumar Bondili, Avinash Bonda, Lingaraj Nayak, Gaurav Chatterjee, Hashmukh Jain, Nikhil Vijay Patkar, Prashant Tembhare, Papagudi Subramanian, Sumeet Gujral, Manju Sengar, Hari Menon, Reena Nair, Bhausaheb Bagal","doi":"10.1007/s12288-024-01777-z","DOIUrl":"https://doi.org/10.1007/s12288-024-01777-z","url":null,"abstract":"<p>Chronic myeloid leukaemia (CML) is caused by balanced translocation t(9::22)(q34;q11) resulting in formation of pathogenic BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. Ongoing treatment with TKI leads to side effects and has financial impact. Teratogenic potential of TKI and growth disturbance also represent an important challenge. Thus, TKI discontinuation in form of treatment free remission (TFR) has emerged as a new and important therapeutic goal. In this retrospective study, we reviewed CML patients who were kept on TFR. Inclusion criteria was patient age ≥ 18 years diagnosed with CML in chronic phase who met the criteria for TFR and opted for same and who were in DMR but stopped TKI for any reason. We analysed the data for baseline characteristics, molecular relapse (MR), survival without molecular relapse (SWMR), TFR duration and factors affecting MR. We included 38 patients in this analysis. Thirty five (92%) patients were treated with imatinib at diagnosis. Median duration of TKI treatment was 135 months. 37 patients (97.5%) achieved DMR on TKI and median time from TKI initiation to DMR was 96 months. Median duration of DMR prior to TKI discontinuation was 41 months. TKI was discontinued after counselling for TFR in 26 patients (68%) while it was discontinued due to intolerance in 10 patients (29%). At median molecular follow up of 25 months, nine patients (23.7%) had molecular relapse. Median SWMR was not reached and 2 year estimated SWMR was 65.2% (95%CI,47.2- 83.2). Of all relapses, 5/9 (55.5%) occurred in the first six months of TFR. On univariate analysis, duration of TKI and duration of DMR were predictive of molecular relapse. On multivariate analysis, none of these factors were found to be significant. This retrospective study suggests that for CML CP patients achieving deep molecular response, discontinuing TKI therapy in real-world settings may be feasible while potentially achieving comparable outcomes.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140942224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}